ArticleFrontiers in immunology2025

Synergistic effects of vedolizumab and JAK 1,2,3 inhibitors in Crohn's disease: insights from a systems biology and artificial intelligence-based approach.

Ignacio Marín-Jiménez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.